Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 roundup with Dr Bishal Gyawali (1/2)

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 5373

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

Dr Gyawali speaks with ecancer reporter Will Davies about highlights from ESMO 2017.

Throughout, Dr Gyawali keeps patient-centric endpoints including quality of life and overall survival as the focus, noting the promise of many trials in extending progression free survival and response, but cautioning that this may not translate to longer, better lives for patients.

Part 2 of his round up, covering results from headline trials including MONARCH 3, PACIFIC and FLAURA, is available here.

For more on STAMPEDE data with Matthew Sydes, click here.

For more on the RANGE trial with Dr Daniel Petrylak, click here.

For more on the Checkmate 214 trial of immunotherapies in mRCC, click here.

For more on COMBI-AD and Checkmate 238 in melanoma, watch the panel comments from the press session here.

For more on the duration of treatment in colorectal cancer, click here.


Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation